Adam M Veness

SVP/General Counsel Adam M Veness sells 30,000 shares for $2.4M via scheduled 10b5-1 plan at DNTH

Adam M Veness, SVP General Counsel and Secretary, executed 2 separate sales totaling 30,000 shares for $2,423,958.16 on 2026-06-17 as part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-18—a scheduled, non-discretionary transaction. The company faces significant headwinds: Revenue declined to $396,000.00 in the latest quarter, annual revenue growth was -67.4%, and net income was negative at $-40,834,000.00 over the most recent full fiscal year. Veness retains 80,000 shares in stock options (Table II derivative holdings), preserving meaningful exposure to the company. The scheduled nature of this sale removes any inference about timing or conviction; however, the magnitude of the revenue contraction and persistent losses underscore the operational challenges facing Dianthus Therapeutics.